Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Ann Rheum Dis. 2022; 0:1–11. doi: 10.1136/annrheumdis-2021-221425
This study, from Vital, et al., analysed pooled data from TULIP-1 and -2 in predefined subgroups of patients with SLE. Treatment with anifrolumab was associated with beneficial responses across efficacy endpoints and was well tolerated. The greatest differences were observed for subgroups of patients with an elevated interferon gene signature, and those with ≥1 abnormal baseline serological test.
IFN-I signalling plays a key role in SLE pathogenesis, and anifrolumab has demonstrated inhibitory effects on IFN-I signalling in patients with SLE. Vital, et al. characterised efficacy and safety of anifrolumab in patients with moderate-to-severe SLE based on interferon gene signature, demographic and clinical subgroups using data pooled from the Phase III TULIP-1 and -2 trials.